



## Urate-stimulating Excretion Agents Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	120	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

### Description

The global Urate-stimulating Excretion Agents market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Urate-stimulating Excretion Agents is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Urate-stimulating Excretion Agents is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Urate-stimulating Excretion Agents is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Urate-stimulating Excretion Agents include Eisai, Teva, Towa Pharmaceutical, Lannett Company, Fuji Yakuhin, Excella and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global Urate-stimulating Excretion Agents market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

### Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Urate-stimulating Excretion Agents Market by Company

Eisai

Teva

Towa Pharmaceutical

Lannett Company

Fuji Yakuhin

Excella

AstraZeneca

### **Urate-stimulating Excretion Agents Segment by Type**

Benzbromarone

Probenecid

Dotinurad

Lesinurad

Other

### **Urate-stimulating Excretion Agents Segment by Application**

Retail Pharmacies

Hospitals and Clinics

Other

### **Urate-stimulating Excretion Agents Segment by Region**

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

## **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urate-stimulating Excretion Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urate-stimulating Excretion Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urate-stimulating Excretion Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### **Chapter 3:**

Detailed analysis of Urate-stimulating Excretion Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

### **Chapter 4:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

### **Chapter 5:**

Production/output, value of Urate-stimulating Excretion Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

### **Chapter 6:**

Consumption of Urate-stimulating Excretion Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

#### **Chapter 7:**

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

#### **Chapter 8:**

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

#### **Chapter 9:**

Analysis of industrial chain, including the upstream and downstream of the industry.

#### **Chapter 10:**

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

#### **Chapter 11:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global Urate-stimulating Excretion Agents Market Size (2021-2032)
  - 2.2.2 Global Urate-stimulating Excretion Agents Sales (2021-2032)
  - 2.2.3 Global Urate-stimulating Excretion Agents Market Average Price (2021-2032)
- 2.3 Urate-stimulating Excretion Agents by Type
  - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
  - 2.3.2 Benzbromarone
  - 2.3.3 Probenecid
  - 2.3.4 Dotinurad
  - 2.3.5 Lesinurad
  - 2.3.6 Other
- 2.4 Urate-stimulating Excretion Agents by Application
  - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.4.2 Retail Pharmacies
  - 2.4.3 Hospitals and Clinics
  - 2.4.4 Other

---

## 3 Market Competitive Landscape by Manufacturers

- 3.1 Global Urate-stimulating Excretion Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urate-stimulating Excretion Agents Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Urate-stimulating Excretion Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Urate-stimulating Excretion Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Urate-stimulating Excretion Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urate-stimulating Excretion Agents, Product Type & Application
- 3.8 Global Manufacturers of Urate-stimulating Excretion Agents, Established Date
- 3.9 Global Urate-stimulating Excretion Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

---

## 4 Manufacturers Profiled

- 4.1 Eisai
  - 4.1.1 Eisai Company Information
  - 4.1.2 Eisai Business Overview
  - 4.1.3 Eisai Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)
  - 4.1.4 Eisai Urate-stimulating Excretion Agents Product Portfolio

4.1.5 Eisai Recent Developments

## 4.2 Teva

4.2.1 Teva Company Information

4.2.2 Teva Business Overview

4.2.3 Teva Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Teva Urate-stimulating Excretion Agents Product Portfolio

4.2.5 Teva Recent Developments

## 4.3 Towa Pharmaceutical

4.3.1 Towa Pharmaceutical Company Information

4.3.2 Towa Pharmaceutical Business Overview

4.3.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.3.4 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio

4.3.5 Towa Pharmaceutical Recent Developments

## 4.4 Lannett Company

4.4.1 Lannett Company Company Information

4.4.2 Lannett Company Business Overview

4.4.3 Lannett Company Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.4.4 Lannett Company Urate-stimulating Excretion Agents Product Portfolio

4.4.5 Lannett Company Recent Developments

## 4.5 Fuji Yakuhin

4.5.1 Fuji Yakuhin Company Information

4.5.2 Fuji Yakuhin Business Overview

4.5.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio

4.5.5 Fuji Yakuhin Recent Developments

## 4.6 Excella

4.6.1 Excella Company Information

4.6.2 Excella Business Overview

4.6.3 Excella Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.6.4 Excella Urate-stimulating Excretion Agents Product Portfolio

4.6.5 Excella Recent Developments

## 4.7 AstraZeneca

4.7.1 AstraZeneca Company Information

4.7.2 AstraZeneca Business Overview

4.7.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Revenue and Gross Margin (2021-2026)

4.7.4 AstraZeneca Urate-stimulating Excretion Agents Product Portfolio

4.7.5 AstraZeneca Recent Developments

---

## 5 Global Urate-stimulating Excretion Agents Market Scenario by Region

5.1 Global Urate-stimulating Excretion Agents Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Urate-stimulating Excretion Agents Sales by Region: 2021-2032

5.2.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021-2026

5.2.2 Global Urate-stimulating Excretion Agents Sales by Region: 2027-2032

5.3 Global Urate-stimulating Excretion Agents Revenue by Region: 2021-2032

5.3.1 Global Urate-stimulating Excretion Agents Revenue by Region: 2021-2026

5.3.2 Global Urate-stimulating Excretion Agents Revenue by Region: 2027-2032

5.4 North America Urate-stimulating Excretion Agents Market Facts & Figures by Country

5.4.1 North America Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032

- 5.4.2 North America Urate-stimulating Excretion Agents Sales by Country (2021-2032)
- 5.4.3 North America Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Urate-stimulating Excretion Agents Market Facts & Figures by Country
  - 5.5.1 Europe Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
  - 5.5.2 Europe Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  - 5.5.3 Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
  - 5.5.4 Germany
  - 5.5.5 France
  - 5.5.6 U.K.
  - 5.5.7 Italy
  - 5.5.8 Russia
  - 5.5.9 Spain
  - 5.5.10 Netherlands
  - 5.5.11 Switzerland
  - 5.5.12 Sweden
  - 5.5.13 Poland
- 5.6 Asia Pacific Urate-stimulating Excretion Agents Market Facts & Figures by Country
  - 5.6.1 Asia Pacific Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
  - 5.6.2 Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  - 5.6.3 Asia Pacific Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
  - 5.6.4 China
  - 5.6.5 Japan
  - 5.6.6 South Korea
  - 5.6.7 India
  - 5.6.8 Australia
  - 5.6.9 Taiwan
  - 5.6.10 Southeast Asia
- 5.7 South America Urate-stimulating Excretion Agents Market Facts & Figures by Country
  - 5.7.1 South America Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
  - 5.7.2 South America Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  - 5.7.3 South America Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
  - 5.7.4 Brazil
  - 5.7.5 Argentina
  - 5.7.6 Chile
- 5.8 Middle East and Africa Urate-stimulating Excretion Agents Market Facts & Figures by Country
  - 5.8.1 Middle East and Africa Urate-stimulating Excretion Agents Market Size by Country: 2021 VS 2025 VS 2032
  - 5.8.2 Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  - 5.8.3 Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (2021-2032)
  - 5.8.4 Egypt
  - 5.8.5 South Africa
  - 5.8.6 Israel
  - 5.8.7 Türkiye
  - 5.8.8 GCC Countries

---

## 6 Segment by Type

- 6.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032)

6.1.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032) & (K Units)

6.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2032)

6.2 Global Urate-stimulating Excretion Agents Revenue by Type (2021-2032)

6.2.1 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2032)

6.3 Global Urate-stimulating Excretion Agents Price by Type (2021-2032)

---

## **7 Segment by Application**

7.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032)

7.1.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032) & (K Units)

7.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2032)

7.2 Global Urate-stimulating Excretion Agents Revenue by Application (2021-2032)

7.2.1 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2032)

7.3 Global Urate-stimulating Excretion Agents Price by Application (2021-2032)

---

## **8 Value Chain and Sales Channels Analysis of the Market**

8.1 Urate-stimulating Excretion Agents Value Chain Analysis

8.1.1 Urate-stimulating Excretion Agents Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Urate-stimulating Excretion Agents Production Mode & Process

8.2 Urate-stimulating Excretion Agents Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Urate-stimulating Excretion Agents Distributors

8.2.3 Urate-stimulating Excretion Agents Customers

---

## **9 Global Urate-stimulating Excretion Agents Analyzing Market Dynamics**

9.1 Urate-stimulating Excretion Agents Industry Trends

9.2 Urate-stimulating Excretion Agents Industry Drivers

9.3 Urate-stimulating Excretion Agents Industry Opportunities and Challenges

9.4 Urate-stimulating Excretion Agents Industry Restraints

---

## **10 Report Conclusion**

## **11 Disclaimer**

# List of Tables and Figures

---

## List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Urate-stimulating Excretion Agents Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Urate-stimulating Excretion Agents Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global Urate-stimulating Excretion Agents Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Urate-stimulating Excretion Agents Revenue of Manufacturers (2021-2026)
- Table 9: Global Urate-stimulating Excretion Agents Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Urate-stimulating Excretion Agents Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Urate-stimulating Excretion Agents Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Urate-stimulating Excretion Agents, Product Type & Application
- Table 14: Global Urate-stimulating Excretion Agents Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Urate-stimulating Excretion Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Eisai Company Information
- Table 19: Eisai Business Overview
- Table 20: Eisai Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Eisai Urate-stimulating Excretion Agents Product Portfolio
- Table 22: Eisai Recent Developments
- Table 23: Teva Company Information
- Table 24: Teva Business Overview
- Table 25: Teva Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Teva Urate-stimulating Excretion Agents Product Portfolio
- Table 27: Teva Recent Developments
- Table 28: Towa Pharmaceutical Company Information
- Table 29: Towa Pharmaceutical Business Overview
- Table 30: Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio
- Table 32: Towa Pharmaceutical Recent Developments
- Table 33: Lannett Company Company Information
- Table 34: Lannett Company Business Overview
- Table 35: Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Lannett Company Urate-stimulating Excretion Agents Product Portfolio
- Table 37: Lannett Company Recent Developments
- Table 38: Fuji Yakuhin Company Information
- Table 39: Fuji Yakuhin Business Overview
- Table 40: Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio
- Table 42: Fuji Yakuhin Recent Developments
- Table 43: Excella Company Information
- Table 44: Excella Business Overview
- Table 45: Excella Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Excella Urate-stimulating Excretion Agents Product Portfolio
- Table 47: Excella Recent Developments

- Table 48: AstraZeneca Company Information
- Table 49: AstraZeneca Business Overview
- Table 50: AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: AstraZeneca Urate-stimulating Excretion Agents Product Portfolio
- Table 52: AstraZeneca Recent Developments
- Table 53: Global Urate-stimulating Excretion Agents Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 54: Global Urate-stimulating Excretion Agents Sales by Region (2021-2026) & (K Units)
- Table 55: Global Urate-stimulating Excretion Agents Sales Market Share by Region (2021-2026)
- Table 56: Global Urate-stimulating Excretion Agents Sales by Region (2027-2032) & (K Units)
- Table 57: Global Urate-stimulating Excretion Agents Sales Market Share by Region (2027-2032)
- Table 58: Global Urate-stimulating Excretion Agents Revenue by Region (2021-2026) & (US\$ Million)
- Table 59: Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2021-2026)
- Table 60: Global Urate-stimulating Excretion Agents Revenue by Region (2027-2032) & (US\$ Million)
- Table 61: Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2027-2032)
- Table 62: North America Urate-stimulating Excretion Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 63: North America Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
- Table 64: North America Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units)
- Table 65: North America Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 66: North America Urate-stimulating Excretion Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 67: Europe Urate-stimulating Excretion Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
- Table 69: Europe Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units)
- Table 70: Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: Europe Urate-stimulating Excretion Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Asia Pacific Urate-stimulating Excretion Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
- Table 74: Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units)
- Table 75: Asia Pacific Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Asia Pacific Urate-stimulating Excretion Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: South America Urate-stimulating Excretion Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: South America Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
- Table 79: South America Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units)
- Table 80: South America Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: South America Urate-stimulating Excretion Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
- Table 84: Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units)
- Table 85: Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: Global Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
- Table 88: Global Urate-stimulating Excretion Agents Sales by Type (2027-2032) & (K Units)
- Table 89: Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
- Table 90: Global Urate-stimulating Excretion Agents Sales Market Share by Type (2027-2032)
- Table 91: Global Urate-stimulating Excretion Agents Revenue by Type (2021-2026) & (US\$ Million)
- Table 92: Global Urate-stimulating Excretion Agents Revenue by Type (2027-2032) & (US\$ Million)
- Table 93: Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026)
- Table 94: Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2027-2032)
- Table 95: Global Urate-stimulating Excretion Agents Price by Type (2021-2026) & (US\$/Unit)
- Table 96: Global Urate-stimulating Excretion Agents Price by Type (2027-2032) & (US\$/Unit)
- Table 97: Global Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
- Table 98: Global Urate-stimulating Excretion Agents Sales by Application (2027-2032) & (K Units)
- Table 99: Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
- Table 100: Global Urate-stimulating Excretion Agents Sales Market Share by Application (2027-2032)
- Table 101: Global Urate-stimulating Excretion Agents Revenue by Application (2021-2026) & (US\$ Million)
- Table 102: Global Urate-stimulating Excretion Agents Revenue by Application (2027-2032) & (US\$ Million)
- Table 103: Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2026)
- Table 104: Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2027-2032)
- Table 105: Global Urate-stimulating Excretion Agents Price by Application (2021-2026) & (US\$/Unit)
- Table 106: Global Urate-stimulating Excretion Agents Price by Application (2027-2032) & (US\$/Unit)
- Table 107: Key Raw Materials
- Table 108: Raw Materials Key Suppliers
- Table 109: Urate-stimulating Excretion Agents Distributors List
- Table 110: Urate-stimulating Excretion Agents Customers List

- Table 111: Urate-stimulating Excretion Agents Industry Trends
- Table 112: Urate-stimulating Excretion Agents Industry Drivers
- Table 113: Urate-stimulating Excretion Agents Industry Restraints
- Table 114: Authors List of This Report

## List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Urate-stimulating Excretion Agents Product Image
- Figure 5: Global Urate-stimulating Excretion Agents Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Urate-stimulating Excretion Agents Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Urate-stimulating Excretion Agents Sales (2021-2032) & (K Units)
- Figure 8: Global Urate-stimulating Excretion Agents Average Price (US\$/Unit) & (2021-2032)
- Figure 9: Benzbromarone Product Image
- Figure 10: Probenecid Product Image
- Figure 11: Dotinurad Product Image
- Figure 12: Lesinurad Product Image
- Figure 13: Other Product Image
- Figure 14: Retail Pharmacies Product Image
- Figure 15: Hospitals and Clinics Product Image
- Figure 16: Other Product Image
- Figure 17: Global Urate-stimulating Excretion Agents Revenue Share by Manufacturers in 2025
- Figure 18: Global Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites & Headquarters
- Figure 19: Global Top 5 and 10 Urate-stimulating Excretion Agents Players Market Share by Revenue in 2025
- Figure 20: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 21: Global Urate-stimulating Excretion Agents Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 22: Global Urate-stimulating Excretion Agents Sales by Region in 2025
- Figure 23: Global Urate-stimulating Excretion Agents Revenue by Region in 2025
- Figure 24: North America Urate-stimulating Excretion Agents Market Size by Country in 2025
- Figure 25: North America Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032)
- Figure 26: North America Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2032)
- Figure 27: United States Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Canada Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Mexico Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Europe Urate-stimulating Excretion Agents Market Size by Country in 2025
- Figure 31: Europe Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032)
- Figure 32: Europe Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2032)
- Figure 33: Germany Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: France Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: U.K. Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Italy Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Russia Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Spain Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Switzerland Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Sweden Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Poland Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Asia Pacific Urate-stimulating Excretion Agents Market Size by Country in 2025
- Figure 44: Asia Pacific Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032)
- Figure 45: Asia Pacific Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2032)
- Figure 46: China Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Japan Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: South Korea Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: India Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Australia Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Taiwan Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Southeast Asia Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: South America Urate-stimulating Excretion Agents Market Size by Country in 2025
- Figure 55: South America Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032)
- Figure 56: South America Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2032)
- Figure 57: Brazil Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 58: Argentina Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Chile Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Middle East and Africa Urate-stimulating Excretion Agents Market Size by Country in 2025
- Figure 61: Middle East and Africa Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032)
- Figure 62: Middle East and Africa Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2032)
- Figure 63: Egypt Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: South Africa Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Israel Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Türkiye Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: GCC Countries Urate-stimulating Excretion Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2032)
- Figure 69: Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2032)
- Figure 70: Global Urate-stimulating Excretion Agents Price (US\$/Unit) by Type (2021-2032)
- Figure 71: Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2032)
- Figure 72: Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2032)
- Figure 73: Global Urate-stimulating Excretion Agents Price (US\$/Unit) by Application (2021-2032)
- Figure 74: Urate-stimulating Excretion Agents Value Chain
- Figure 75: Urate-stimulating Excretion Agents Production Mode & Process
- Figure 76: Direct Comparison with Distribution Share
- Figure 77: Distributors Profiles
- Figure 78: Urate-stimulating Excretion Agents Industry Opportunities and Challenges